Intensity-modulated and image-guided radiation therapy for head and neck cancers

Frontiers of Radiation Therapy and Oncology

Volumn 43, Issue , 2011, Pages 217-254

  Chu, Karen Pat Ming ^a   Le, Quynh Thu ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; PACLITAXEL;

ALGORITHM; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; CYBERKNIFE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ESOPHAGUS STRICTURE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; HEAD; HEAD AND NECK CANCER; HUMAN; IMAGE GUIDED RADIATION THERAPY; INTENSITY MODULATED RADIATION THERAPY; MEDICAL ERROR; METASTASIS; MONOTHERAPY; NASOPHARYNX CARCINOMA; NECK; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CANCER; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PATIENT MOBILITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION FIELD; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALIVARY GLAND; SHOULDER; TREATMENT PLANNING; WEIGHT REDUCTION; XEROSTOMIA;

HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED;

DISEASES; DOSIMETRY; TUMORS;

CONVENTIONAL RADIATION THERAPY; CRITICAL STRUCTURES; HEAD AND NECK ANATOMIES; HEAD-AND-NECK CANCER; IMAGE-GUIDED RADIATION THERAPY; INTENSITY-MODULATED; INTENSITY-MODULATED RADIATION THERAPY; LOCOREGIONAL CONTROL;

RADIOTHERAPY;

EID: 79958227918     PISSN: 00719676     EISSN: 16623789     Source Type: Book Series    
DOI: 10.1159/000322437     Document Type: Article

References (61)

1. Cozzi L, Fogliata A, Bolsi A, Nicolini G, Bernier J: Three-dimensional conformal vs intensitymodulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys 2004; 58: 617-624. (Pubitemid 38142489)
2. de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY: Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006; 64: 363-373. (Pubitemid 43083420)
3. Webster GJ, Rowbottom CG, Mackay RI: Accuracy and precision of an IGRT solution. Med Dosim 2009; 34: 99-106.
4. Dirix P, Vandecaveye V, De Keyzer F, Op de Beeck K, Poorten VV, Delaere P, Verbeken E, Hermans R, Nuyts S: Diffusion-weighted MRI for nodal staging of head and neck squamous cell carcinoma: impact on radiotherapy planning. Int J Radiat Oncol Biol Phys 2010; 76: 761-766.
5. Roh JL, Yeo NK, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY: Utility of 2-(18F) fluoro-2- deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol 2007; 43: 887-893. (Pubitemid 47369251)
6. Rodrigues RS, Bozza FA, Christian PE, Hoffman JM, Butterfield RI, Christensen CR, Heilbrun M, Wiggins RH 3rd, Hunt JP, Bentz BG, Hitchcock YJ, Morton KA: Comparison of whole-body PET/ CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. J Nucl Med 2009; 50: 1205-1213.
7. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507. (Pubitemid 36706537)
8. Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, Schuller DE: Impact of (18F)-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117: 1173-1179. (Pubitemid 47015665)
9. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, Lütolf UM, Steinert HC, Von Schulthess GK: Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003; 57: 853-863. (Pubitemid 37194314)
10. Paulino AC, Koshy M, Howell R, Schuster D, Davis LW: Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005; 61: 1385-1392. (Pubitemid 40470419)
11. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, Grégoire V: Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004; 233: 93-100. (Pubitemid 39280962)
12. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, Maxim P, Quon A, Graves EE, Loo BW Jr, Le QT: Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1335-1341.
13. MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, Danna M, Inoue T, Deniaud- Alexandre E, Schipani S, Watanabe N, Dondi M, Jeremic B: Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009; 91: 85-94.
14. Burri RJ, Rangaswamy B, Kostakoglu L, Hoch B, Genden EM, Som PM, Kao J: Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. Int J Radiat Oncol Biol Phys 2008; 71: 682-688.
15. Wu K, Ung YC, Hornby J, Freeman M, Hwang D, Tsao MS, Dahele M, Darling G, Maziak DE, Tirona R, Mah K, Wong CS: PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings? Int J Radiat Oncol Biol Phys 2010; 77: 699-706.
16. Ashamalla H, Guirgius A, Bieniek E, Rafla S, Evola A, Goswami G, Oldroyd R, Mokhtar B, Parikh K: The impact of positron emission tomography/ computed tomography in edge delineation of gross tumor volume for head and neck cancers. Int J Radiat Oncol Biol Phys 2007; 68: 388-395. (Pubitemid 46694159)
17. Murakami R, Uozumi H, Hirai T, Nishimura R, Shiraishi S, Ota K, Murakami D, Tomiguchi S, Oya N, Katsuragawa S, Yamashita Y: Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007; 68: 377-382. (Pubitemid 46694156)
18. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL, EORTC 24971/TAX 323 Study Group: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704.
19. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI, TAX 324 Study Group: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715. (Pubitemid 350005152)
20. Tannock IF: Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol 1989; 16: 83-101. (Pubitemid 19258947)
21. Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM: Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 358-363. (Pubitemid 47380104)
22. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD: Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 2004; 26: 890-896. (Pubitemid 39299309)
23. Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS: Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 75: 725-733.
24. Rosenthal DI, Fuller CD, Ang KK, Brizel DM, Eisbruch A, Le QT, Lee NY, O'Sullivan B, Duppen J, Rasch CRN: Pre- and postinduction chemotherapy target volume delineation in head and neck cancer: preliminary results from an expert panel. Int J Radiat Oncol Biol Phys 2009; 75:S431.
25. Geets X, Tomsej M, Lee JA, Duprez T, Coche E, Cosnard G, Lonneux M, Grégoire V: Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007; 85: 105-115. (Pubitemid 47570061)
26. Hwang AB, Bacharach SL, Yom SS, Weinberg VK, Quivey JM, Franc BL, Xia P: Can positron emission tomography (PET) or PET/computed tomography (CT) acquired in a nontreatment position be accurately registered to a head-and-neck radiotherapy planning CT? Int J Radiat Oncol Biol Phys 2009; 73: 578-584.
27. Nabili V, Zaia B, Blackwell KE, Head CS, Grabski K, Sercarz JA: Positron emission tomography: poor sensitivity for occult tonsillar cancer. Am J Otolaryngol 2007; 28: 153-157. (Pubitemid 46702352)
28. Dong MJ, Zhao K, Lin XT, Zhao J, Ruan LX, Liu ZF: Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose- PET/computed tomography in detection of unknown primary tumor: a metaanalysis of the literature. Nucl Med Commun 2008; 29: 791-802.
29. Yeung HW, Grewal RK, Gonen M, Schöder H, Larson SM: Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003; 44: 1789-1796. (Pubitemid 39663311)
30. El-Haddad G, Alavi A, Mavi A, Bural G, Zhuang H: Normal variants in (18F)-fluorodeoxyglucose PET imaging. Radiol Clin North Am 2004; 42: 1063-1081. (Pubitemid 39361460)
31. Pentenero M, Cistaro A, Brusa M, Ferraris MM, Pezzuto C, Carnino R, Colombini E, Valentini MC, Giovanella L, Spriano G, Gandolfo S: Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma. Head Neck 2008; 30: 1488-1496.
32. Hong TS, Tome WA, Chappell RJ, Chinnaiyan P, Mehta MP, Harari PM: The impact of daily set-up variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 61: 779-788. (Pubitemid 40247973)
33. La TH, Chao M, Xing L, Le Q: Evaluation of intrafraction motion in head and neck cancer during radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:S681-S682.
34. Dong L, Chen YP, Lindberg ME, Garden AS, Rosenthal DI, Sejpal SV, Shah SJ, Morrison WH, Ang KK, Schwartz DL: Interfractional movement of the larynx and oropharynx during radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75:S16-S17.
35. McRackan TR, Watkins JM, Herrin AE, Garrett- Mayer EM, Sharma AK, Day TA, Gillespie MB: Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope 2008; 118: 1180-1185.
36. Dirix P, Abbeel S, vanstraelen B, Hermans R, Nuyts S: Dysphagia after chemoradiation for head and neck squamous cell carcinoma: doseeffect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2009; 75: 385-392.
37. Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA: Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010; 76: 403-409.
38. Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen EE, Blair E, Vokes E, Haraf DJ: Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancers. Arch Otolaryngol Head Neck Surg 2008; 134: 1060-1065.
39. Mohan R, Zhang X, Wang H, Kang Y, Wang X, Liu H, Ang KK, Kuban D, Dong L: Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes. Int J Radiat Oncol Biol Phys 2005; 61: 1258-1266. (Pubitemid 40340922)
40. Dijkema T, Raaijmakers CP, Ten Haken RK, Roesink JM, Braam PM, Houweling AC, Moerland MA, Eisbruch A, Terhaard CH: Parotid gland function after radiotherapy: the combined Michigan and Utrecht experience. Int J Radiat Oncol Biol Phys 2010; 78: 449-453.
41. Pehlivan B, Pichenot C, Castaing M, Auperin A, Lefkopoulos D, Arriagada R, Bourhis J. Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients. Acta Oncol 2009; 48: 440-445.
42. Den RB, Doemer A, Kubicek G, Bednarz G, Galvin JM, Keane WM, Xiao Y, Machtay M: Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensitymodulated radiotherapy: a prospective study. Int J Radiat Oncol Biol Phys 2010; 76: 1353-1359.
43. Bucci M, Xia P, Lee N, Fischbein N, Kramer A, Weinberg V, Akazawa C, Cabrera A, Fu KK, Quivey JM: Intensity modulated radiation therapy for carcinoma of the nasopharynx: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2004; 60:S317-S318.
44. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ: Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64: 57-62. (Pubitemid 41831209)
45. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee B, Chan AT: Treatment of nasopharyngeal carcinoma with intensity- modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004; 60: 1440-1450. (Pubitemid 39601861)
46. Fang FM, Chien CY, Tsai WL, Chen HC, Hsu HC, Lui CC, Huang TL, Huang HY: Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy - a longitudinal study. Int J Radiat Oncol Phys Biol 2008; 72: 356-364.
47. Zhao C, Xiao W, Han F, Lu L, Huang S, Wu S, Chen C, Chen J, Lin C, Deng X: Long-term results and prognostic factors of primary nasopharyngeal carcinoma patients treated with intensity modulated-radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75:S630.
48. Tham IW, Hee SW, Yeo RM, Salleh PB, Lee J, Tan TW, Fong KW, Chua ET, Wee JT: Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy - the National Cancer Centre Singapore experience. Int J Radiat Oncol Biol Phys 2009; 75: 1481-1486.
49. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009; 27: 3684-3690.
50. Palazzi M, Orlandi E, Bossi P, Pignoli E, Potepan P, Guzzo M, Franceschini M, Scaramellini G, Cantu G, Licitra L, Olmi P, Tomatis S: Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience. Int J Radiat Oncol Biol Phys 2009; 74: 774-780.
51. Le QT, Tate D, Koong A, Gibbs IC, Chang SD, Adler JR, Pinto HA, Terris DJ, Fee WE, Goffinet DR: Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 1046-1054. (Pubitemid 36794036)
52. Hara, W, Loo BW, Goffinet DR, Chang SD, Adler JR, Pinto HA, Fee WE, Kaplan MJ, Fischbein NJ, Le QT: Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008; 71: 393-400.
53. Chao KS, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO, Haughey BH, Spector GJ, Sessions DG: Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004; 59: 43-50. (Pubitemid 38501505)
54. Garden AS, Morrison WH, Wong PF, Tung SS, Rosenthal DI, Dong L, Mason B, Perkins GH, Ang KK: Disease-control rates following intensity- modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 438-444. (Pubitemid 46108322)
55. Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW, Lee NY, Yom SS, Phillips TL, Quivey JM: Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California San Francisco experience. Cancer 2008; 113: 497-507.
56. Daly ME, Le QT, Maxim PM, Loo BW Jr, Kaplan MJ, Fischbein NJ, Pinto H, Chang DT: Intensitymodulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010; 76: 1339-1346.
57. Hodge CW, Bentzen SM, Wong G, Palazzi-Churas KL, Wiederholt PA, Gondi V, Richards GM, Hartig GK, Harari PM: Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. Int J Radiat Oncol Biol Phys 2007; 69: 1032-1041. (Pubitemid 47625846)
58. Lee NY, de Arruda FF, Puri DR, Wolden SL, Narayana A, Mechalakos J, Venkatraman ES, Kraus D, Shaha A, Shah JP, Pfister DG, Zelefsky MJ: A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 966-974. (Pubitemid 44633520)
59. Sanguineti G, Gunn GB, Endres EJ, Chaljub G, Cheruvu P, Parker B: Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008; 72: 737-746.
60. Schoenfeld GO, Amdur RJ, Morris CG, Li JG, Hinerman RW, Mendenhall WM: Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 71: 377-385.
61. Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR, Ang KK: Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2010; 76: 1333-1338.